Quality of Life Analyses from the Randomized, Open-Label, Phase III PointBreak Study of Pemetrexed-Carboplatin-Bevacizumab followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer Article

cited authors

  • Spigel, David R.; Patel, Jyoti D.; Reynolds, Craig H.; Garon, Edward B.; Hermann, Robert C.; Govindan, Ramaswamy; Olsen, Mark R.; Winfree, Katherine B.; Chen, Jian; Liu, Jingyi; Guba, Susan C.; Socinski, Mark A.; Bonomi, Philip

authors

Publication Date

  • February 1, 2015

webpage

published in

category

keywords

  • Bevacizumab
  • Functional assessment of cancer therapy
  • Nonsquamous non-small-cell lung cancer
  • Paclitaxel
  • Pemetrexed

start page

  • 353

end page

  • 359

volume

  • 10

issue

  • 2